4 unchanged sentences
Oth er Information
+Added: The following table describes for the three months ended March 31, 2026 each trading arrangement under which the Company's officers, directors or director affiliated investment funds adopted, materially modified, or terminated any contracts, instructions, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
+Added: Name and Position
+Added: Rule 10b5-1 (1)
+Added: Total Shares of
+Added: Robert Lechleider , Chief Medical Officer
+Added: March 26, 2026
+Added: December 31, 2026
+Added: Robert Lechleider , Chief Medical Officer
+Added: March 26, 2026
+Added: December 31, 2026
+Added: Kinney Horn , Chief Business Officer
+Added: March 30, 2026
+Added: January 15, 2027
+Added: Isaac Barchas , Director
+Added: March 31, 2026
+Added: March 15, 2027
+Added: ABHMC II LLC , Investor (4)
+Added: March 31, 2026
+Added: December 31, 2027
+Added: Arsenal Bridge Venture II-B LLC, Investor (5)
+Added: March 31, 2026
+Added: December 31, 2027
+Added: (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: (2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
+Added: (3) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 24, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: (4) The Rule 10b5-1 trading plan was adopted by ABHMC II LLC, or ABHMC.
+Added: The shares held by ABHMC II LLC were received following an in-kind distribution of the Company's common stock from Arsenal Bridge Venture II, LLC, or ABV II, in accordance with its operating agreement.
+Added: ABHMC is the managing member of ABV II.
+Added: Barchas, a member of the Company's Board of Directors, is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABHMC.
+Added: Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.
+Added: (5) The Rule 10b5-1 trading plan was adopted by Arsenal Bridge Venture II-B LLC, or ABV II-B.
+Added: Barchas, a member of the Company's Board of Directors, is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II-B.
+Added: Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.
EXHIBIT INDEX
6 unchanged sentences
(incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed October 6, 2020).
+Added: Amendment No.
+Added: 3 to License Agreement, dated March 27, 2026, by and between the Company and Bristol-Myers Squibb Company.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Interactive Data File (Form 10‑Q for the Quarterly Period ended September 30, 2025 filed in XBRL).
+Added: Interactive Data File (Form 10‑Q for the Quarterly Period ended March 31, 2026 filed in XBRL).
The financial information contained in the XBRL-related documents is “unaudited” and “unreviewed.” The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.
1 unchanged sentence
* Filed or furnished herewith.
+Added: Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and is the type of information the Company treats as private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IMMUNOME, INC.
−Removed: November 6, 2025
+Added: /s/ Clay Siegall, Ph.
+Added: Clay Siegall, Ph.
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 6, 2025
/s/ Max Rosett
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.